SPPI News and Press, Spectrum Pharmaceuticals Inc. From 03/17/22

Spectrum Pharmaceuticals, Inc. (SPPI) Q4 2021 Earnings Conference Call March 17, 2022, 04:30 PM ET Company Participants Kurt Gustafson - CFO Tom Riga - President & CEO Francois Lebel - EVP & Chief Medical Officer Conference Call Participants Kevin Strang - Jefferies Ed White - H.C. Wa...

Shares of Spectrum Pharmaceuticals (NASDAQ:SPPI) are down 2% in post-market trading even though its Q4 2021 results beat on the bottom line. Its net loss in the quarter of ~$39.7M was nearly the same as the ~$39.8M loss in the year-ago period. On a per share basis, net loss was -$0....

Spectrum Pharmaceuticals press release (NASDAQ:SPPI): Q4 Non-GAAP EPS of -$0.17 beats by $0.01. Spectrum reported cash, cash equivalents, and marketable securities of approximately $100.6 million as of December 31, 2021, compared to $180 million at December 31, 2020. For further details see...

Eflapegrastim BLA resubmitted to FDA Poziotinib NDA accepted for FDA review in previously treated patients with NSCLC harboring HER2 exon 20 insertion mutations, PDUFA date November 24, 2022 Positive poziotinib results in treatment naïve patients with NSCLC harbor...

Spectrum Pharmaceuticals (NASDAQ:SPPI) is scheduled to announce Q4 earnings results on Wednesday, March 16th, after market close. The consensus EPS Estimate is -$0.18 (+10.0% Y/Y) and the consensus Revenue Estimate is $0M Over the last 2 years, SPPI has beaten EPS estimates 25% of the time an...

Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biopharmaceutical company focused on novel and targeted oncology therapies, today announced it will host a conference call to discuss the fourth quarter and full year 2021 financial results and provide a corporate update on Thursday, March 17...

Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biopharmaceutical company focused on novel and targeted oncology therapies, today announced the appointment of Juhyun Lim to its Board of Directors. “We are delighted to have Ms. Lim join Spectrum’s Board of Directors,ȁ...

Spectrum Pharmaceuticals (NASDAQ:SPPI) said the group 4 of a trial called ZENITH20 met its main goal evaluating poziotinib in certain patients with non-small lung cancer (NSCLC) who had not received prior therapy. The ZENITH20 study consists of seven cohorts. This data was from 70 f...

Data presented at ESMO TAT from Cohort 4 of the ZENITH20 clinical trial met the primary endpoint Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biopharmaceutical company focused on novel and targeted oncology therapies, today announced the presentation of safety and effica...

Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biopharmaceutical company focused on novel and targeted oncology therapies, today announced an oral presentation on poziotinib at the European Society for Medical Oncology (ESMO) Targeted Anticancer Therapies (TAT) Congress 2022 being held vi...